SIMG
AKBA icon

Sonora Investment Management Group’s Akebia Therapeutics AKBA Stock Holding History

Sonora Investment Management Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$32.8K Hold
12,000
– – ﹤0.01% 302
2025
Q2 		$43.7K Hold
12,000
– – ﹤0.01% 299
2025
Q1 		$23K Hold
12,000
– – ﹤0.01% 300
2024
Q4 		$22.8K Buy
12,000
+2,000
+20% +$3.47K ﹤0.01% 298
2024
Q3 		$13.2K Hold
10,000
– – ﹤0.01% 288
2024
Q2 		$18.3K Hold
10,000
– – ﹤0.01% 283
2024
Q1 		$18.3K Hold
10,000
– – ﹤0.01% 284
2023
Q4 		$12.4K Hold
10,000
– – ﹤0.01% 276
2023
Q3 		$11.4K Hold
10,000
– – ﹤0.01% 265
2023
Q2 		$9.15K Hold
10,000
– – ﹤0.01% 264
2023
Q1 		$5.6K Sell
10,000
-1,085
-10% -$829 ﹤0.01% 274
2022
Q4 		$6.4K Hold
11,085
– – ﹤0.01% 268
2022
Q3 		$4K Hold
11,085
– – ﹤0.01% 209
2022
Q2 		$4K Hold
11,085
– – ﹤0.01% 246
2022
Q1 		$8K Sell
11,085
-2,000
-15% -$4.28K ﹤0.01% 225
2021
Q4 		$30K Buy
+13,085
New +$35.7K ﹤0.01% 213

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Sonora Investment Management Group's AKBA Position: Q3 2025 in Review

Sonora Investment Management Group held its Akebia Therapeutics (AKBA) position steady in Q3 2025 at 12,000 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Sonora Investment Management Group first reported a position in AKBA in Q4 2021 and has held it in 16 quarters since. The position peaked at $43.7K in Q2 2025. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Sonora Investment Management Group held 12,000 shares of Akebia Therapeutics worth $32.8K as of Q3 2025.
  • Sonora Investment Management Group left its Akebia Therapeutics share count unchanged in Q3 2025.
  • Akebia Therapeutics made up ﹤0.01% of Sonora Investment Management Group's portfolio in Q3 2025, its #302 holding.
  • Sonora Investment Management Group first reported a position in Akebia Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Sonora Investment Management Group's Akebia Therapeutics position peaked at $43.7K in Q2 2025.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Sonora Investment Management Group's 13F filing for Q3 2025, filed 7 Oct 2025.